The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2014 | Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Christoph Röllig (Universitätsklinikum Dresden, Dresden, Germany) discusses the phase II Study Alliance Leukemia (SAL)-Soraml trial, which evaluated sorafenib versus placebo in addition to standard therapy in younger patients (18–60 years old) with newly diagnosed acute myeloid leukaemia. improves event-free survival and relapse-free survival rate in younger patients with newly-diagnosed acute myeloid leukaemia.
